CN104031126B - A kind of natural killer T cells activator polypeptide and application thereof - Google Patents
A kind of natural killer T cells activator polypeptide and application thereof Download PDFInfo
- Publication number
- CN104031126B CN104031126B CN201410295889.0A CN201410295889A CN104031126B CN 104031126 B CN104031126 B CN 104031126B CN 201410295889 A CN201410295889 A CN 201410295889A CN 104031126 B CN104031126 B CN 104031126B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- natural killer
- sequence
- tumor
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 26
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 24
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 24
- 210000000581 natural killer T-cell Anatomy 0.000 title abstract description 23
- 239000012190 activator Substances 0.000 title description 12
- 239000003814 drug Substances 0.000 claims abstract description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 10
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 9
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 19
- 206010040070 Septic Shock Diseases 0.000 abstract description 7
- 230000004083 survival effect Effects 0.000 abstract description 7
- 230000004913 activation Effects 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 4
- 230000001629 suppression Effects 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 238000009509 drug development Methods 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 19
- 102000018779 Replication Protein C Human genes 0.000 description 6
- 108010027647 Replication Protein C Proteins 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 101100216185 Oryza sativa subsp. japonica AP25 gene Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- ABLJDBFJPUWQQB-DCAQKATOSA-N Cys-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N ABLJDBFJPUWQQB-DCAQKATOSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 description 1
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 1
- DRRXXZBXDMLGFC-IHRRRGAJSA-N Lys-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN DRRXXZBXDMLGFC-IHRRRGAJSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- XWBJLKDCHJVKAK-KKUMJFAQSA-N Phe-Arg-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N XWBJLKDCHJVKAK-KKUMJFAQSA-N 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- FZEUTKVQGMVGHW-AVGNSLFASA-N Ser-Phe-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZEUTKVQGMVGHW-AVGNSLFASA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical group O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410295889.0A CN104031126B (en) | 2014-06-27 | 2014-06-27 | A kind of natural killer T cells activator polypeptide and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410295889.0A CN104031126B (en) | 2014-06-27 | 2014-06-27 | A kind of natural killer T cells activator polypeptide and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104031126A CN104031126A (en) | 2014-09-10 |
CN104031126B true CN104031126B (en) | 2016-10-12 |
Family
ID=51462142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410295889.0A Active CN104031126B (en) | 2014-06-27 | 2014-06-27 | A kind of natural killer T cells activator polypeptide and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104031126B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101735982A (en) * | 2009-12-31 | 2010-06-16 | 浙江中赢控股集团有限公司 | Method for amplifying lymphocyte by interleukin 15 receptor and interleukin 2 complex |
CN102460161A (en) * | 2009-04-09 | 2012-05-16 | 洛菲厄斯生物科学有限责任公司 | Method for polypeptide transfer into cells |
CN103517917A (en) * | 2010-11-25 | 2014-01-15 | 伊姆耐特有限责任公司 | Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells |
-
2014
- 2014-06-27 CN CN201410295889.0A patent/CN104031126B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102460161A (en) * | 2009-04-09 | 2012-05-16 | 洛菲厄斯生物科学有限责任公司 | Method for polypeptide transfer into cells |
CN101735982A (en) * | 2009-12-31 | 2010-06-16 | 浙江中赢控股集团有限公司 | Method for amplifying lymphocyte by interleukin 15 receptor and interleukin 2 complex |
CN103517917A (en) * | 2010-11-25 | 2014-01-15 | 伊姆耐特有限责任公司 | Modulation of antigen immunogenicity by addition of epitopes recognized by nkt cells |
Non-Patent Citations (1)
Title |
---|
Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice;Liu Yawei et.al;《J Clin Invest》;20110104;第121卷(第1期);249-264 * |
Also Published As
Publication number | Publication date |
---|---|
CN104031126A (en) | 2014-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018508196A (en) | Anti-aging compounds and uses thereof | |
CN108047312A (en) | A kind of stable polypeptide targeting proteins chimer molecules and its preparation method and application | |
US20160022762A1 (en) | Agent for Eliminating Multidrug Resistance | |
CN102271713B (en) | Neurotensin-derived branched peptides and uses thereof | |
Guan et al. | Clinical development of histone deacetylase inhibitor romidepsin | |
CN104031126B (en) | A kind of natural killer T cells activator polypeptide and application thereof | |
CN113274485A (en) | Application of scorpion venom polypeptide Smp24 in preparation of antitumor drugs | |
Jähde et al. | Nigericin enhances mafosfamide cytotoxicity at low extracellular pH | |
CN110946948A (en) | Application of Huafengdan in preparation of anti-breast cancer drugs | |
CN104004056B (en) | A kind of about Cyclin D protein inhibitor polypeptide and application thereof | |
CN115518165A (en) | Application of PAD4 inhibitor loaded by CRGD sequence peptide modified chitosan in preparation of anti-tumor metastasis drugs | |
CN104031125B (en) | Natural killer T cells activator polypeptide and application thereof | |
CN104045689B (en) | A kind of about somatostatin receptor agonist polypeptide and application thereof | |
CN103130871B (en) | Preparation method and application of prodrug of endopeptidase activated doxorubicin | |
CN106432423B (en) | A kind of alpha-helix polypeptide and application thereof | |
CN104017053B (en) | A kind of PER2 protein agonist polypeptide and application thereof | |
CN104017054B (en) | PER2 protein agonist polypeptide and application thereof | |
CN104592353A (en) | Anti-tumor peptide variant NC2 and application thereof | |
CN104017051B (en) | A kind of Cyclin D protein inhibitor polypeptide and application thereof | |
CN104031123B (en) | About natural killer T cells activator polypeptide and application thereof | |
CN104031124B (en) | A kind of about natural killer T cells activator polypeptide and application thereof | |
CN104045691B (en) | Npas2 protein agonist polypeptide and application thereof | |
Wu et al. | Tracking interactions between TAMs and CAFs mediated by arginase‐induced proline production during immune evasion of HCC | |
RU2682039C1 (en) | Peptide, possessing anti-tumor and anti-metastatic activity, and finished dosage form based thereon | |
CN107753476B (en) | Application of composition containing 4-acetyl-android quinuclidine-B in preparing medicine for inhibiting growth of ovarian cancer cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Yuzhen Inventor after: Sun Qiaojuan Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160912 Address after: 266000 Licang, Qingdao, No. nine East water road, No. 320, No. Applicant after: Gu Yukui Address before: High tech Zone Suzhou city Jiangsu province 215000 Chuk Yuen Road No. 209 Applicant before: Suzhou Pu Luo Da Biotechnology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Yuzhen Inventor after: Sun Qiaojuan Inventor after: Song Yunjuan Inventor after: Hu Shishu Inventor after: Shen Yan Inventor before: Wang Yuzhen Inventor before: Sun Qiaojuan |
|
COR | Change of bibliographic data | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161026 Address after: 518000 Guangdong city of Shenzhen province Qianhai Shenzhen Hong Kong cooperation zone before Bay Road No. 1 building 201 room A (located in Shenzhen Qianhai business secretary Co. Ltd.) Patentee after: Shenzhen Kuang Yi Biotechnology Co., Ltd. Address before: 266000 Licang, Qingdao, No. nine East water road, No. 320, No. Patentee before: Gu Yukui |